Trials / Sponsors / Cassava Sciences, Inc.

Cassava Sciences, Inc.

Industry · 9 registered clinical trials.

Status	Trial	Phase	Started
Completed	A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function Hepatic Insufficiency	Phase 1	2024-06-26
Completed	Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose Absorption, Metabolism, Excretion	Phase 1	2024-02-07
Terminated	Open-label Extension for Phase 3 Clinical Trials of Simufilam Alzheimer Disease	Phase 3	2022-11-07
Terminated	Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease Alzheimer's Disease	Phase 2	2022-05-12
Terminated	Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease Alzheimer Disease	Phase 3	2021-11-18
Completed	Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Alzheimer Disease	Phase 3	2021-11-03
Completed	Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers Healthy Volunteers	Phase 1	2021-05-04
Completed	Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients Alzheimer Disease	Phase 2	2020-03-24
Completed	PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Alzheimer Disease	Phase 2	2019-09-09